salicylates and Neuralgia

Topics: Activities of Daily Living; Arthritis, Rheumatoid; Bursitis; Chloroquine; Diagnosis, Differential; Finger Joint; Gold; Gout; Hot Temperature; Humans; Hydroxychloroquine; Methylprednisolone; Neuralgia; Osteoarthritis; Pain; Physical Examination; Physical Exertion; Physical Therapy Modalities; Prednisolone; Rest; Salicylates; Synovectomy; Triamcinolone; Wrist Joint

Topics: Analgesics; Arthritis, Rheumatoid; Aspirin; Headache; Humans; Ischemia; Kinetics; Neoplasms; Neuralgia; Phenacetin; Phenylbutazone; Salicylates; Time Factors; Wounds and Injuries

Current treatment strategies for painful diabetic neuropathy (PDN) include oral medications, which are costly and may have adverse effects. Topical therapies have been used for PDN with some benefit. Nutmeg has certain properties that may be effective in ameliorating neuropathic pain. The purpose of this study was to determine whether topical nutmeg extracts can reduce pain or improve the quality of life in PDN sufferers.. This study was a randomized, double-blind, placebo-controlled trial.. It was conducted at a primary care center in Trinidad, Caribbean.. Seventy-four (74) diabetic subjects who met criteria for painful neuropathy were recruited.. Participants were randomized to receive either topical nutmeg extracts (NEMM; mace oil [2%], nutmeg oil [14%], methyl salicylate [6%], menthol [6%], and coconut oil) or placebo (MM; methyl salicylate [6%], menthol [6%], coconut oil, and alcohol).. Outcome measures of pain and quality of life were assessed using the Brief Pain Inventory for Diabetic Painful Neuropathy and Neuropathic Pain Symptom Inventory.. An intention-to-treat analysis was done for 24 male and 50 female subjects (30-85 years) with an average duration of diabetes of 11 years. Significant reductions in worst and average pain scores were seen within each group (p ≤ 0.001). Similarly significant reductions were also noted for interference with walking, sleep, and mood scores as well as burning, pins and needles, and tingling scores within each group (p<0.05). There were no statistically significant differences between both groups after 4 weeks for any outcome measure.. In this trial topical, nutmeg extracts did not add to the improvements observed in PDN symptoms during 4 weeks treatment with preparations containing menthol and methyl salicylate. Further research designed to test the individual components of the topical therapies used in this study may clarify their benefit.

Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Analgesics; Diabetic Neuropathies; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Male; Menthol; Middle Aged; Myristica; Neuralgia; Oils, Volatile; Plant Oils; Salicylates

The aim of this investigation was to elucidate whether the analgesic effect was due to the local aspirin or to the systemic drug. This was done by comparing skin and plasma levels of acetylsalicylic acid (ASA) and salicylic acid (SA) after topically administered ASA/diethyl ether (ADE) mixture in acute herpetic neuralgia (AHN) and postherpetic neuralgia (PHN). The analgesia and the plasma and skin levels of ASA were also determined after oral administration of aspirin.. Nineteen patients, 11 (57.9%) with AHN and 8 (42.1 %) with PHN were given, on different days, a single 500-mg oral dose of ASA or a topical dose (750 mg) of (ADE) daubed onto the painful skin. The analgesic effect was assessed by means of a visual analogue scale (VAS). Overall pain relief was graded as: excellent, good, fair, or poor. AHN as well as PHN patients had severe pain at baseline (6.83 and 5.93). Levels of ASA and SA in plasma and in the stratum corneum after adhesive tape stripping of the treated area were determined by HPLC.. After ADE application, the analgesic effect was very rapid and VAS scores were lower than at baseline. Pain significantly decreased by 82.6% after topical and 15.4% after oral ASA. After ADE, 95% of the patients had excellent or good pain relief, but after oral administration 79% of the patients had a poor response. Pain relief was similar in the two subgroups after ADE. Skin concentrations of ASA, but not of SA, after ADE were about 80- to 100-fold those after oral administration. Levels of ASA and SA in plasma after oral administration were similar to those previously found, but after ADE were undetectable or very low. Patients with excellent pain relief showed a trend towards higher ASA skin concentrations.. The analgesic effect can be obtained only after topical administration, because by this route the skin levels of ASA are much higher than after oral administration. The mechanism is exclusively local; there are no active drugs in plasma after topical administration.

Topics: Acute Disease; Administration, Oral; Administration, Topical; Aged; Analgesics; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Over Studies; Double-Blind Method; Ether; Female; Herpes Zoster; Herpesviridae Infections; Humans; Male; Middle Aged; Neuralgia; Pain; Pain Measurement; Salicylates; Salicylic Acid; Skin; Solvents; Treatment Outcome

Ras and c-Raf constitute an important part of mitogen-activated protein (MAP) kinase family as Ras/Raf/MEK/ERK2 signaling cascade and the role of MAP kinases has been well defined in neuropathic pain. The present study investigates the analgesic potential of farnesyl thiosalicylic acid, a novel Ras inhibitor, and GW 5074, a selective c-Raf1 inhibitor, in vincristine-induced neuropathic pain. Peripheral neuropathy was induced in rats by administering vincristine (50 μg/kg i.p.) for 10 consecutive days. Pain development was assessed on 14th day in terms of cold allodynia; mechanical hyperalgesia and mechanical allodynia by performing acetone test, pin-prick and von frey tests, respectively. Farnesyl thiosalicylic acid and GW 5074 were injected intrathecally on 14th day following vincristine administration. Administration of vincristine produced significant neuropathic pain manifestations in terms of cold and mechanical allodynia, and mechanical hyperalgesia. Single intrathecal administration of farnesyl thiosalicylic acid (5 and 10 μg) as well as GW 5074 (2 and 4 μg) significantly attenuated vincristine-induced hyperalgesia and allodynia. The analgesic effects of farnesyl thiosalicylic acid and GW 5074 in vincristine model suggests that pharmacological inhibition of Ras and c-Raf-1 signalling may be potentially useful for managing neuropathic pain.

Topics: Analgesics; Animals; Farnesol; Female; Indoles; Injections, Spinal; Male; Neuralgia; Phenols; Rats; Rats, Wistar; Salicylates; Vincristine

Topics: Advertising; History, 19th Century; History, 20th Century; Humans; Neuralgia; Rheumatic Diseases; Salicylates

Topics: Back Pain; Drug Combinations; Evaluation Studies as Topic; Gels; Heparin; Humans; Menthol; Neuralgia; Pain; Salicylates

Topics: Analgesics; Autopsy; Drug Hypersensitivity; Female; Humans; Injections, Intravenous; Middle Aged; Neuralgia; Salicylates

Topics: Amides; Heparin; Humans; Joint Diseases; Neuralgia; Salicylates; Spinal Diseases; Tissue Extracts

Topics: Biological Transport; Electrolytes; Humans; Iontophoresis; Joint Diseases; Neuralgia; Salicylates

Topics: Ascorbic Acid; Neuralgia; Rheumatic Diseases; Salicylates; Succinates; Vitamins